An appropriate CIBINQO patient should meet all of the following:
• Platelets ≥150 × 10³/mm³
• Absolute lymphocyte count (ALC) ≥0.5 × 10³/mm³
• Absolute neutrophil count (ANC) ≥1.2 × 10³/mm³
• Haemoglobin (Hb) ≥10 g/dL

Serious infections:

• Treatment must not be initiated in patients with an active, serious systemic infection
• If a patient develops a serious infection, sepsis, or opportunistic infection, dose interruption should be considered until the infection is controlled

Vaccines:​​​​​

• Use of live, attenuated vaccines should be avoided during or immediately prior to treatment. Prior to initiating treatment with this medicinal product, it is recommended that patients be brought up to date with all immunisations, including prophylactic herpes zoster vaccinations, in agreement with current immunisation guidelines

Tuberculosis:

• Patients should be screened for tuberculosis (TB) before starting treatment and yearly screening for patients in highly endemic areas for TB should be considered. CIBINQO must not be given to patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, preventive therapy for latent TB should be started prior to initiation of CIBINQO

Viral reactivation:

• Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy and during therapy with CIBINQO